Biodesix ranked top proteomics solutions company by life sciences review magazine

Boulder, colo.--( business wire )--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the company was named the leading proteomics solutions company in the u.s. by life sciences review magazine , featured in the december 2022 issue, “top 10 proteomics solutions companies of 2022.” biodesix is a market leader with over 15 years of experience in the field of clinical proteomics. the company's expertise focuses on profiling the patient's immune response to their cancer with blood-based proteomic solutions, in addition to genomic insights. biodesix's core technologies and extensive machine learning and transparent ai expertise allow for identifying clinically relevant proteomic differences in patient populations to help guide treatment strategy. to date, biodesix has performed over 125,000 proteomic tests for research and clinical use.
BDSX Ratings Summary
BDSX Quant Ranking